Fundraising FoxDharmacon
2 known investors
Find your way into Dharmacon
Dharmacon Reagents provides synthetic oligonucleotides, gene modulation, and gene editing solutions for functional genomics research, enabling researchers to study genetic networks and advance therapeutic discovery. The company offers a comprehensive range of tools for DNA, RNA, and protein-level research, including RNAi, CRISPR gene editing, and screening libraries for academic and commercial researchers.
Investors · 2
Telegraph Hill Partnerslisted by Telegraph Hill PartnersSan Francisco · $2M – $8M
How we know: Telegraph Hill Partners's portfolio page · Not right? Tell us
Boulder VenturesreportedBoulder · $1M – $4M
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Dharmacon do?
- Dharmacon Reagents provides synthetic oligonucleotides, gene modulation, and gene editing solutions for functional genomics research, enabling researchers to study genetic networks and advance therapeutic discovery. The company offers a comprehensive range of tools for DNA, RNA, and protein-level research, including RNAi, CRISPR gene editing, and screening libraries for academic and commercial researchers.
- Who are Dharmacon's investors?
- Dharmacon's investors include Telegraph Hill Partners, Boulder Ventures.